Norman Ng: Would the inclusion of China-developed PD-1 drugs enhance the fairness of healthcare?
Norman Ng, Director of Patient Advocacy and Public Affairs at Healthcare Thinkers, shared a post on LinkedIn:
“Would the inclusion of China-developed PD-1 drugs in the Hong Kong Hospital Authority Drug Formulary is a step towards enhancing the fairness of healthcare resource allocation ?
Integrating China-developed PD-1 drugs into the Hospital Authority’s drug formulary would mark a pivotal step toward equitable healthcare. This move could broaden access for cancer patients while fostering diversity and competition in Hong Kong’s medical market.
But critical questions remain:
What long-term impacts might this have on Hong Kong’s healthcare system?
Can the vision of ‘Shared costs for minor illnesses, protection from poverty due to major diseases’ truly be realized—and if so, how?”
More posts featuring Norman Ng.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023